Climb Bio reports initial Phase 1b data showing platelet responses for budoprutug in immune thrombocytopenia trial

Climb Bio

Climb Bio

CLYM

0.00
  • Climb Bio presented initial Phase 1b data at EHA Congress 2026 for budoprutug in primary immune thrombocytopenia.
  • Early results showed favorable safety and tolerability, with no serious safety signals reported in the cohorts disclosed.
  • The study showed clear biological activity, with B-cell suppression and meaningful, durable platelet responses in heavily pretreated patients.
  • Responses were observed in some patients previously treated with rituximab, supporting potential differentiation in a hard-to-treat population.
  • Enrollment continues in the high-dose cohort, with additional data expected by year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606110700PRIMZONEFULLFEED9735316) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.